GSK And Novartis Double Down On Neglected Disease R&D Spend
Big Pharma Steps Up
Executive Summary
GSK will invest over $1bn over the next decade to develop medicines that combat malaria, neglected tropical diseases and antibiotic resistance, while Novartis is putting in $250m over the next five years.
You may also be interested in...
Argenx Eyes Hat-Trick Of Successful Launches For Vyvgart After CHMP Thumbs-Up
Anant Murthy, general manager of Argenx Europe, tells Scrip that the commercial infrastructure is in place for Vyvgart to enjoy a strong launch for the rare neuromuscular disorder which will mirror those seen in the US and Japan.
Moderna Makes Major mRNA Commitment To UK
The US biotech major has unveiled plans to open a new research and manufacturing center in the UK, which signals the start of detailed talks with the government about establishing a long-term partnership.
AstraZeneca Closes Amyloidosis Gap On Alnylam After Eplontersen Win
AstraZeneca is preparing a US filing for hereditary transthyretin-mediated amyloid polyneuropathy for eplontersen, which it hopes will compete with Pfizer and Alnylam's therapies in that rare disease space.